Priority 21 from the Mesothelioma PSP

UNCERTAINTY: What is the current best method (e.g. contrast enhanced MRI vs PET) to accurately assess disease progression in mesothelioma patients? (JLA PSP Priority 21)
Overall ranking 21
JLA question ID 0025/21 
Explanatory note Not available for this PSP
Evidence No systematic reviews or studies identified
Health Research Classification System category Cancer
Extra information provided by this PSP
Original uncertainty examples How do you accurately assess disease progression?
Comparison None identified
Submitted by Health Professional
Outcomes to be measured Detection of progression
PSP information
PSP unique ID 0025
PSP name Mesothelioma
Total number of uncertainties identified by this PSP. 53  (To see a full list of all uncertainties identified, please see the detailed spreadsheet held on the JLA website)
Date of priority setting workshop 16 December 2014